Silexion Therapeutics Collaborates With Evonik on Advanced siRNA Formulation Development
Silexion Therapeutics Corp. recently announced its ongoing collaboration with Evonik, a global leader in specialty chemicals, for the development of an advanced siRNA formulation aimed at enhancing cancer treatment efficacy.
Through this existing collaboration, Evonik’s proprietary biodegradable long-acting PLGA (RESOMER) microparticle formulation was used for SIL-204, Silexion’s next-generation siRNA candidate. This innovative formulation has demonstrated high efficacy in preclinical models using mice with human pancreatic tumor cell lines carrying various KRAS mutations. By leveraging Evonik’s formulation expertise, Silexion aims to deliver sustained-release RNAi therapy, allowing for more effective targeting of KRAS mutations—one of the most challenging genetic drivers in oncology.
“We are pleased to share the details of our collaboration with Evonik Corporation, which has led to this advanced delivery system for SIL-204,” said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. “Through this ongoing collaboration, we’ve leveraged Evonik’s expertise to create a sustained-release formulation that enhances the stability and targeting of SIL-204, as part of our commitment to advancing RNAi therapies for KRAS-driven cancers.”
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company’s first-generation product, LODER, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information, visit https://silexion.com.
Total Page Views: 206
